Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/WDR11_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/WDR11_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/WDR11_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/WDR11_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
GO:00069038 | Esophagus | ESCC | vesicle targeting | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
GO:00352647 | Esophagus | ESCC | multicellular organism growth | 80/8552 | 132/18723 | 3.84e-04 | 2.22e-03 | 80 |
GO:00990222 | Esophagus | ESCC | vesicle tethering | 10/8552 | 11/18723 | 2.54e-03 | 1.08e-02 | 10 |
GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
GO:00069037 | Oral cavity | OSCC | vesicle targeting | 38/7305 | 45/18723 | 4.49e-10 | 1.19e-08 | 38 |
GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
GO:0099022 | Oral cavity | OSCC | vesicle tethering | 10/7305 | 11/18723 | 5.78e-04 | 3.30e-03 | 10 |
GO:00352646 | Oral cavity | OSCC | multicellular organism growth | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
GO:005165624 | Skin | cSCC | establishment of organelle localization | 178/4864 | 390/18723 | 2.18e-17 | 2.32e-15 | 178 |
GO:00069039 | Skin | cSCC | vesicle targeting | 28/4864 | 45/18723 | 3.26e-07 | 6.57e-06 | 28 |
GO:005165018 | Skin | cSCC | establishment of vesicle localization | 70/4864 | 161/18723 | 1.02e-06 | 1.82e-05 | 70 |
GO:005164816 | Skin | cSCC | vesicle localization | 73/4864 | 177/18723 | 6.36e-06 | 8.92e-05 | 73 |
GO:00990223 | Skin | cSCC | vesicle tethering | 8/4864 | 11/18723 | 1.56e-03 | 9.60e-03 | 8 |
GO:005165620 | Thyroid | PTC | establishment of organelle localization | 193/5968 | 390/18723 | 2.21e-13 | 1.15e-11 | 193 |
GO:005165019 | Thyroid | PTC | establishment of vesicle localization | 89/5968 | 161/18723 | 6.38e-10 | 1.97e-08 | 89 |
GO:005164817 | Thyroid | PTC | vesicle localization | 94/5968 | 177/18723 | 3.54e-09 | 9.45e-08 | 94 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
WDR11 | SNV | Missense_Mutation | | c.2483N>T | p.Ala828Val | p.A828V | Q9BZH6 | protein_coding | deleterious(0.02) | benign(0.015) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | | c.3592C>T | p.Leu1198Phe | p.L1198F | Q9BZH6 | protein_coding | tolerated(0.54) | benign(0.001) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | novel | c.2513C>T | p.Thr838Ile | p.T838I | Q9BZH6 | protein_coding | tolerated(0.24) | benign(0) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
WDR11 | SNV | Missense_Mutation | | c.2414N>T | p.Thr805Met | p.T805M | Q9BZH6 | protein_coding | deleterious(0.01) | possibly_damaging(0.877) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | novel | c.2810N>G | p.His937Arg | p.H937R | Q9BZH6 | protein_coding | tolerated(1) | benign(0.057) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | novel | c.3265T>A | p.Trp1089Arg | p.W1089R | Q9BZH6 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
WDR11 | SNV | Missense_Mutation | | c.494C>A | p.Ser165Tyr | p.S165Y | Q9BZH6 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | novel | c.3026N>T | p.Gln1009Leu | p.Q1009L | Q9BZH6 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | rs745952055 | c.3331C>T | p.Arg1111Trp | p.R1111W | Q9BZH6 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
WDR11 | SNV | Missense_Mutation | rs867397877 | c.1411C>T | p.Arg471Cys | p.R471C | Q9BZH6 | protein_coding | deleterious(0) | benign(0.003) | TCGA-D1-A16Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |